Literature DB >> 12782184

Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes.

Su-Jane Wang1.   

Abstract

Cannabinoid receptors are widely expressed in the brain and have been shown to regulate synaptic transmission through a presynaptic mechanism. Using synaptosomal preparation, I show here that 2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)-pyrrolo-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55212-2) strongly depressed 4-aminopyridine-evoked glutamate release in a concentration-dependent manner, and this effect was reversed by the selective cannabinoid CB(1) receptor antagonist 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide (AM 281). The inhibitory modulation by WIN 55212-2 was not due to a decrease in synaptosomal excitability or a direct effect on the release machinery because WIN 55212-2 did not alter 4-aminopyridine-mediated depolarization and ionomycin-induced glutamate release. In addition, the WIN 55212-2-mediated inhibition of glutamate release was blocked by the G(i)/G(o) protein inhibitor pertussis toxin, but not by the protein kinase A inhibitor 2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo-benzodiazocine-10-carboxylic acid, hexyl ester (KT 5720). Furthermore, this inhibitory effect was associated with a decrease in 4-aminopyridine-evoked Ca(2+) influx, which could be completely prevented in synaptosomes pretreated with the N- and P/Q-type Ca(2+) channel blockers. Together, these observations indicate that activation of cannabinoid CB(1) receptors inhibit 4-aminopyridie-evoked glutamate release from hippocampal synaptosomes through a inhibitory G protein to suppress N- and P/Q-type Ca(2+) channel activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782184     DOI: 10.1016/s0014-2999(03)01734-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Inflammation and aging: can endocannabinoids help?

Authors:  Yannick Marchalant; Holly M Brothers; Gary L Wenk
Journal:  Biomed Pharmacother       Date:  2008-03-14       Impact factor: 6.529

Review 2.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

Review 4.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

5.  Inhibition by anandamide and synthetic cannabimimetics of the release of [3H]D-aspartate and [3H]GABA from synaptosomes isolated from the rat hippocampus.

Authors:  M D'Amico; C Cannizzaro; P Preziosi; M Martire
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

Review 6.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

7.  Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.

Authors:  Deepak Cyril D'Souza; Daniel J Fridberg; Patrick D Skosnik; Ashley Williams; Brian Roach; Nagendra Singh; Michelle Carbuto; Jacqueline Elander; Ashley Schnakenberg; Brian Pittman; R Andrew Sewell; Mohini Ranganathan; Daniel Mathalon
Journal:  Neuropsychopharmacology       Date:  2012-02-15       Impact factor: 7.853

8.  Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.

Authors:  Patrick D Skosnik; Mihály Hajós; Jose A Cortes-Briones; Chad R Edwards; Brian P Pittman; William E Hoffmann; Andrew R Sewell; Deepak C D'Souza; Mohini Ranganathan
Journal:  Neuropharmacology       Date:  2018-03-28       Impact factor: 5.250

9.  In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.

Authors:  Faith Borgan; Heikki Laurikainen; Mattia Veronese; Tiago Reis Marques; Merja Haaparanta-Solin; Olof Solin; Tarik Dahoun; Maria Rogdaki; Raimo Kr Salokangas; Max Karukivi; Marta Di Forti; Federico Turkheimer; Jarmo Hietala; Oliver Howes
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

10.  Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals.

Authors:  Tzu-Yu Lin; Cheng-Wei Lu; Chia-Chan Wu; Shu-Kuei Huang; Su-Jane Wang
Journal:  Int J Mol Sci       Date:  2015-03-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.